Organoids Market Report 2026

The organoids market size has grown exponentially in recent years. It will grow from $4.82 billion in 2025 to $5.9 billion in 2026 at a compound annual growth rate (CAGR) of 22.3%. The growth in the historic period can be attributed to advancements in stem cell technology, rising demand for alternative models to animal testing, increasing research in tissue engineering, growing investments in biotechnology R&D, early adoption of organoid models by academic research institutes.

The organoids market size is expected to see exponential growth in the next few years. It will grow to $13.13 billion in 2030 at a compound annual growth rate (CAGR) of 22.2%. The growth in the forecast period can be attributed to expansion of personalized medicine applications, increasing pharmaceutical industry collaborations with organoid research companies, growth in regenerative medicine initiatives, rising government and private funding for organoid-based research, development of organoid biobanks for disease modeling. Major trends in the forecast period include rising adoption of organoids in drug discovery and personalized medicine, increasing use of organoids in regenerative medicine and tissue engineering, growing applications of organoids in infectious disease pathology studies, increasing development of disease-specific organoids for targeted therapeutics, rising integration of organoid models in preclinical drug efficacy and toxicity testing.

The rising incidence and prevalence of chronic and infectious diseases is expected to drive growth in the organoid market in the coming years. Chronic diseases are conditions lasting more than a year that require ongoing medical treatment. Organoids provide a reliable platform to study various chronic diseases and their treatments, offering rapid insights into pathogen biology and drug responses. For example, in June 2024, according to the National Health Service, a UK-based publicly funded healthcare system, 3,615,330 people were registered with a GP as having non-diabetic hyperglycemia (pre-diabetes) in 2023, up from 3,065,825 in 2022 - an increase of nearly 18%. The growing prevalence of chronic diseases is therefore supporting the expansion of the organoid market.

Companies in the organoid market are developing revolutionary platforms, such as organoid panel screening systems, to accelerate preclinical oncology drug discovery and gain a competitive advantage. An organoid panel screening platform allows simultaneous testing across a collection of organoids to evaluate drug responses efficiently. For instance, in November 2023, Crown Bioscience, a US-based contract research organization (CRO) and JSR Life Sciences company, launched OrganoidXplore, a large-scale organoid panel screening platform designed to accelerate preclinical oncology drug discovery. The platform leverages Crown Bioscience’s assay-ready (AR) organoid technology, providing robust performance, shorter project timelines, and reduced costs compared to traditional methods. OrganoidXplore enables reliable drug response comparisons while accurately replicating the genomic, morphological, and pathophysiological characteristics of original tumors.

In December 2024, Merck KGaA, a Germany-based life sciences company, acquired HUB Organoids Holding B.V. for an undisclosed amount. The acquisition aims to strengthen Merck’s next-generation biology portfolio by integrating HUB Organoids’ proprietary technology, including model generation, assay development, and high-throughput screening capabilities. HUB Organoids Holding B.V., based in the Netherlands, provides organoid technology services and holds foundational patents in organoid biology.

Major companies operating in the organoids market are Cellesce Ltd., STEMCELL Technologies, HUB Organoids, DefiniGEN, OcellO B.V., Organoid Therapeutics, InSphero AG, Axol Bioscience Ltd., TissUse GmbH, Epithelix Sàrl, SUN Bioscience, Prellis Biologics, Epistem, MIMETAS BV, Organoidsciences Ltd., Zenit Science, Biomorgan, TheWell Bioscience Inc., CN Bio Innovations Ltd., TARA Biosystems, Nortis Inc., Newcells Biotech, Known Medicine, Dynomics Inc., CHA Biotech Co Ltd, Tempus AI Inc.

North America was the largest region in the organoids market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global organoids market size forecast period. The regions covered in the organoids market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the organoids market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the organoids market by increasing costs of imported stem cells, culture media, and laboratory reagents essential for organoid development. The research and pharmaceutical applications segments in north america, europe, and asia-pacific have been particularly affected due to reliance on cross-border supply chains. Increased tariffs have led to higher operational costs and slower procurement timelines for biotech companies and research institutions. However, tariffs have also incentivized local production of reagents and culture systems, fostering regional supply chain resilience and self-sufficiency.

The organoids market research report is one of a series of new reports that provides organoids market statistics, including organoids industry global market size, regional shares, competitors with a organoids market share, detailed organoids market segments, market trends and opportunities, and any further data you may need to thrive in the organoids industry. This organoids market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Organoids are three-dimensional, miniature tissue cultures derived from stem cells. They are used in personalized and regenerative medicine, gene repair, and transplantation therapy.

The main organoid products include hepatic organoids, colorectal organoids, intestinal organoids, and others. Hepatic organoids are functional, three-dimensional in vitro models of the liver, used to study liver development, regeneration, disease modeling, and related research questions. Organoids are typically derived from pluripotent stem cells or organ-specific adult stem cells and are applied in areas such as developmental biology, infectious disease pathology, regenerative medicine, drug toxicity and efficacy testing, drug discovery, and personalized medicine. They are used by hospitals and diagnostic centers, biotechnology and pharmaceutical companies, and other end users.

The organoids market consists of sales of epithelial organoid, embryonic organoid, and cerebral organoid. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.